secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2025-12-22T23:59:59+00:00
Accession:  0001386570-25-000030
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Niagen acquires QUB NR patent portfolio; $1M upfront, annual payments through 2038
--------------------------------------------------------------------------------

- One-time ~$1M payment to QUB for accrued royalties through 2024; annual $500K+£35K through 2038.
- Additional one-time payments of $1.5M in 2035 and $2M in 2038 as consideration for patent assignment and release.
- QUB assigned all patent rights to ChromaDex; prior JOMA and License Agreement terminated with royalty obligations released.
- Acquired portfolio includes composition-of-matter patents for NR salt forms (e.g., NR Malate, NR Tartrate) and global rights.
- Niagen now sole owner of core NR IP estate with >90 patents worldwide; CEO cites enhanced control and shareholder protection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000138657025000030/0001386570-25-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000138657025000030/cdxc-20251218.htm
  HTML page:      https://secwatch.observer/filing/0001386570-25-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer